Novavax's (NVAX.US) share price jumped more than 20% after the biotech company said Canada had agreed to pay $350 million for Covid vaccines that were previously due to be delivered. The settlement, in the case of NVAX, is significant because the company's management expressed doubts about its viability earlier in the year.
According to the SEC filing, the Canadian government's payment will be made in two equal instalments in 2023. It is worth mentioning that the vaccines for Covid-19 are the company's only commercial product.
The company's shares are currently testing the limitation formed by the 100-day exponential moving average (purple curve). Source: xStation 5
US Open: Wall Street Starts September Under Pressure as Oil Returns to the Spotlight
Daily summary: Geopolitics and debt continue to weigh on valuations
US OPEN: Market Cornered After Jackson Hole
PG&E shares plunge 18% 🚩 Panic hits U.S. utility stocks exposed to wildfire liabilities